Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope
- 1 December 2000
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 7 (23) , 2036-2040
- https://doi.org/10.1038/sj.gt.3301335
Abstract
Enhanced green fluorescent protein (EGFP) is a novel marker gene product, which is readily detectable using techniques of fluorescence microscopy, flow cytometry, or macroscopic imaging. In the present studies, we have examined the immunogenicity of EGFP in murine models. A stable transfectant of the transplantable CMS4 sarcoma of BALB/c origin expressing EGFP, CMS4-EGFP-Zeo, was generated. Splenocytes harvested from mice immunized with a recombinant adenovirus expressing EGFP (Ad-EGFP) were restimulated in vitro with CMS4-EGFP-Zeo. Effector lymphocytes displayed strong cytotoxicity against CMS4-EGFP-Zeo, but not against mock-transfected CMS4-Zeo tumor cells. A number of candidate H2-Kd-binding peptides derived from the EGFP protein were chosen according to an epitope prediction program and synthesized. These peptides were tested for their ability to bind to H2-Kd molecules and stimulate IFNγ-production by splenocytes harvested from Ad-EGFP-immunized mice. Using this methodology, the peptide, HYLSTQSAL (corresponding to EGFP200–208) which strongly binds to H2-Kd molecules, was identified as a naturally occurring epitope of EGFP. These results should facilitate the use of EGFP as a model tumor antigen in BALB/c mice.Keywords
This publication has 25 references indexed in Scilit:
- Immune response to green fluorescent protein: implications for gene therapyGene Therapy, 1999
- Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen β-galactosidase and the BALB/c Meth A p53 tumor-specific antigenGene Therapy, 1999
- Induction of tumor antigen-specific immunity using plasmid DNA immunization in miceCancer Gene Therapy, 1999
- Genetically modified bone marrow‐derived dendritic cells expressing tumor‐associated viral or “self” antigens induce antitumor immunity in vivoEuropean Journal of Immunology, 1997
- DNA VACCINESAnnual Review of Immunology, 1997
- FACS-optimized mutants of the green fluorescent protein (GFP)Gene, 1996
- Green Flourescent Protein: The green revolutionCurrent Biology, 1995
- Improved green fluorescenceNature, 1995
- Green Fluorescent Protein as a Marker for Gene ExpressionScience, 1994
- Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytesEuropean Journal of Immunology, 1993